RLYB (Rallybio Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RLYB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Helen M Boudreau | Director | M | — | — |
| 2026-05-20 | Daniel Schneeberger | 10%+ Owner | Buy | — | — |
| 2026-05-15 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | — | — |
| 2026-05-13 | Daniel Schneeberger | 10%+ Owner | Buy | — | — |
| 2026-05-06 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | — | — |
| 2026-02-23 | Jonathan I Lieber | Chief Financial Officer | MIXED | — | — |
| 2026-02-20 | MARTIN MACKAY | Director | A | — | — |
| 2026-02-20 | RONALD HUNT | Director | A | — | — |
| 2025-05-15 | Helen M Boudreau | Director | A | — | — |
| 2025-05-15 | Wendy Chung | Director | A | — | — |
| 2025-05-15 | RONALD HUNT | Director | A | — | — |
| 2025-05-15 | Robert Lorne Hopfner | Director | A | — | — |
| 2025-05-15 | Hui Liu | Director | A | — | — |
| 2025-05-15 | Paula Soteropoulos | Director | A | — | — |
| 2025-05-15 | MARTIN MACKAY | Director | A | — | — |
| 2025-05-15 | Christine A Nash | Director | A | — | — |
| 2025-02-19 | Jonathan I Lieber | Chief Financial Officer | A | — | — |
| 2025-02-19 | Stephen Uden | Chief Executive Officer | A | — | — |
| 2025-02-19 | Steven Ryder | Chief Medical Officer | A | — | — |
| 2025-01-06 | MARTIN MACKAY | Director | A | — | — |
| 2025-01-06 | Robert Lorne Hopfner | Director | A | — | — |
| 2025-01-06 | Hui Liu | Director | A | — | — |
| 2025-01-06 | RONALD HUNT | Director | A | — | — |
| 2024-05-17 | Wendy Chung | Director | A | — | — |
| 2024-05-17 | Christine A Nash | Director | A | — | — |
| 2024-05-17 | Robert Lorne Hopfner | Director | A | — | — |
| 2024-05-17 | RONALD HUNT | Director | A | — | — |
| 2024-05-17 | Helen M Boudreau | Director | A | — | — |
| 2024-05-17 | Hui Liu | Director | A | — | — |
| 2024-05-17 | KUSH PARMAR | Director | A | — | — |
| 2024-05-17 | Paula Soteropoulos | Director | A | — | — |
| 2024-02-16 | MARTIN MACKAY | Executive Chairman | A | — | — |
| 2024-02-16 | Steven Ryder | Chief Medical Officer | A | — | — |
| 2024-02-16 | Jonathan I Lieber | Chief Financial Officer | A | — | — |
| 2024-02-16 | Stephen Uden | Chief Executive Officer | A | — | — |
| 2024-01-04 | RONALD HUNT | Director | A | — | — |
| 2024-01-04 | KUSH PARMAR | Director | A | — | — |
| 2023-05-19 | Robert Lorne Hopfner | Director | A | — | — |
| 2023-05-19 | Helen M Boudreau | Director | A | — | — |
| 2023-05-19 | KUSH PARMAR | Director | A | — | — |
| 2023-05-19 | Christine A Nash | Director | A | — | — |
| 2023-05-19 | Hui Liu | Director | A | — | — |
| 2023-05-19 | Wendy Chung | Director | A | — | — |
| 2023-05-19 | RONALD HUNT | Director | A | — | — |
| 2023-05-19 | Paula Soteropoulos | Director | A | — | — |
| 2023-03-16 | Jonathan I Lieber | See Remarks | Buy | — | — |
| 2023-03-09 | SCOTT M ROCKLAGE | 10%+ Owner | Sell | — | — |
| 2023-03-09 | KUSH PARMAR | Director | Sell | — | — |
| 2023-02-06 | MARTIN MACKAY | Chief Executive Officer | A | — | — |
| 2023-02-06 | Steven Ryder | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 926,152 | — |
| — | 10%+ Owner | 909,843 | — |
| — | 10%+ Owner | 524,347 | — |
| — | 10%+ Owner | 309,871 | — |
| — | Director | 297,371 | — |
| — | Director | 291,599 | — |
| — | Director | 249,239 | — |
| — | Director | 211,798 | — |
| — | — | 211,798 | — |
| — | 10%+ Owner | 175,762 | — |
| — | 10%+ Owner | 162,760 | — |
| — | 10%+ Owner | 156,469 | — |
| — | Chief Executive Officer | 89,790 | — |
| — | Executive Chairman | 89,329 | — |
| — | See Remarks | 34,076 | — |
| — | Director | 6,542 | — |
| — | Chief Financial Officer | 4,904 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RLYB quote page; the site-wide leaderboard is on the insider transactions hub.